ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis
The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The...
Saved in:
Published in | Frontiers in oncology Vol. 12; p. 1018396 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
30.09.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).A multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.The analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).The ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients. |
---|---|
AbstractList | The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).A multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.The analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).The ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients.ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients. BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or Antagonist-II (PIVKA-II) and AFP-L3 (included in the GALAD score but not in the ASAP score). The current study sought to compare the diagnostic performance of each score to detect HCC among patients infected with hepatitis C virus (HCV).MethodsA multicenter case-control study was undertaken in which blood samples were collected from HCVinfected patients with and without HCC. Using the area under the receiver operating characteristic curve (AUROC), ASAP and GALAD scores were compared relative to diagnostic performance to detect any stage HCV-HCC and early-stage HCV-HCC.ResultsThe analytic cohort included 168 HCV-HCC patients and a control group of 193 HCV-infected patients. The ASAP score had a higher AUROC to detect any stage HCV-HCC versus the GALAD score, both in the overall group (0.917 vs. 0.894, P=0.057) and in the cirrhosis subgroup (0.909 vs. 0.889, P=0.132). Similar results were noted relative to the detection of early-stage HCV-HCC, whether defined by BCLC staging (stage 0-A: 0.898 vs. 0.860, P=0.026) or 8th TNM staging (stage I: 0.899 vs. 0.870, P=0.070). In subgroup analysis to detect AFP-negative HCV-HCC, the ASAP score also demonstrated a higher AUROC than the GALAD score to detect any stage HCV-HCC in the AFP-negative subgroup (0.815 vs. 0.764, P=0.063).ConclusionsThe ASAP score had better diagnostic performance for early detection of HCV-HCC compared with the GALAD score. The ASAP score may be preferrable to the GALAD score for HCC screening and surveillance among HCV-infected patients. |
Author | Pawlik, Timothy M. Yin, Dong-Xu Liang, Lei Gu, Li-Hui Wang, Ming-Da Tong, Xiang-Min Zhu, Hong Lau, Wan Yee Yang, Tian Liu, Si-Yu Shen, Feng Sun, Li-Yang Xing, Hao Guan, Ming-Cheng Li, Chao Yao, Lan-Qing |
AuthorAffiliation | 6 School of Clinical Medicine, Hangzhou Medical College , Hangzhou , China 7 Eastern Hepatobiliary Clinical Research Institute (EHCRI), Third Affiliated Hospital of Navy Medical University , Shanghai , China 9 Faculty of Medicine, the Chinese University of Hong Kong, Shatin , Hong Kong, SAR , China 5 Department of Medical Oncology, the First Affiliated Hospital of Soochow University , Suzhou , China 4 Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Zhejiang , China 2 The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Hangzhou , China 8 Department of Surgery, Ohio State University, Wexner Medical Center , Columbus, OH , United States 1 Department of Laboratory Medicine, Lishui Municipal Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical Un |
AuthorAffiliation_xml | – name: 2 The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Hangzhou , China – name: 5 Department of Medical Oncology, the First Affiliated Hospital of Soochow University , Suzhou , China – name: 8 Department of Surgery, Ohio State University, Wexner Medical Center , Columbus, OH , United States – name: 3 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University) , Shanghai , China – name: 1 Department of Laboratory Medicine, Lishui Municipal Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University , Lishui , China – name: 7 Eastern Hepatobiliary Clinical Research Institute (EHCRI), Third Affiliated Hospital of Navy Medical University , Shanghai , China – name: 9 Faculty of Medicine, the Chinese University of Hong Kong, Shatin , Hong Kong, SAR , China – name: 4 Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College , Zhejiang , China – name: 6 School of Clinical Medicine, Hangzhou Medical College , Hangzhou , China |
Author_xml | – sequence: 1 givenname: Si-Yu surname: Liu fullname: Liu, Si-Yu – sequence: 2 givenname: Chao surname: Li fullname: Li, Chao – sequence: 3 givenname: Li-Yang surname: Sun fullname: Sun, Li-Yang – sequence: 4 givenname: Ming-Cheng surname: Guan fullname: Guan, Ming-Cheng – sequence: 5 givenname: Li-Hui surname: Gu fullname: Gu, Li-Hui – sequence: 6 givenname: Dong-Xu surname: Yin fullname: Yin, Dong-Xu – sequence: 7 givenname: Lan-Qing surname: Yao fullname: Yao, Lan-Qing – sequence: 8 givenname: Lei surname: Liang fullname: Liang, Lei – sequence: 9 givenname: Ming-Da surname: Wang fullname: Wang, Ming-Da – sequence: 10 givenname: Hao surname: Xing fullname: Xing, Hao – sequence: 11 givenname: Hong surname: Zhu fullname: Zhu, Hong – sequence: 12 givenname: Timothy M. surname: Pawlik fullname: Pawlik, Timothy M. – sequence: 13 givenname: Wan Yee surname: Lau fullname: Lau, Wan Yee – sequence: 14 givenname: Feng surname: Shen fullname: Shen, Feng – sequence: 15 givenname: Xiang-Min surname: Tong fullname: Tong, Xiang-Min – sequence: 16 givenname: Tian surname: Yang fullname: Yang, Tian |
BookMark | eNp9kU1rFTEUhgepYK39Ae6ydDM1X_MRF8JwrbVwQaEK7kLm5KRNyZ1ck0yhO3-6M96LWBdmk_Ce8z45yfuyOpnihFX1mtELIXr11sUJLjjl_IJR1gvVPqtOOReyVlJ8P_nr_KI6z_meLqttKKPitPo53AxfyA3EhOQBU54zuRq2w4ej5GIiFgtC8XEi0ZE73Jvii89kUycMpqA9aBEwhDmYRMAk8FPcmXdkILs5FA84FVwLGWuIU0kxEDOZ8Jh9flU9dyZkPD_uZ9W3j5dfN5_q7eer682wrUFKXuquUchdKzt0DlpulQIuwY6GNdI2yik5wgi9Q4EKgMqxH1EaKRhTDAUdxVl1feDaaO71PvmdSY86Gq9_CzHdapOWUQPqRlHjpGX9CFaKEYyiFJhlUhghrV1Z7w-s_Tzu0K7PSyY8gT6tTP5O38YHrZquZX2zAN4cASn-mDEXvfN5_UAzYZyz5h1vFeddI5dWdmiFFHNO6P5cw6he09dr-npNXx_TXzzdPx7wxawRLtP48B_nL-bWuyo |
CitedBy_id | crossref_primary_10_1097_HEP_0000000000000953 crossref_primary_10_1002_jhbp_12070 crossref_primary_10_1016_j_cyto_2023_156442 crossref_primary_10_11569_wcjd_v31_i10_404 crossref_primary_10_1097_HEP_0000000000001196 crossref_primary_10_1097_HC9_0000000000000422 crossref_primary_10_1159_000536211 crossref_primary_10_2147_JHC_S499966 |
Cites_doi | 10.1016/j.jhep.2019.08.025 10.2147/JHC.S271790 10.1053/gast.1997.v112.pm9024300 10.1016/j.jhep.2011.12.001 10.1111/j.1440-1746.2008.05487.x 10.1080/00365521.2018.1459824 10.1158/1055-9965.EPI-13-0870 10.3748/wjg.v19.i3.339 10.1158/1055-9965.EPI-18-0281 10.1053/j.gastro.2018.01.064 10.1111/j.1365-2036.2010.04370.x 10.2741/4668 10.1373/clinchem.2019.308965 10.1016/j.jhep.2021.07.004 10.1002/hep.29913 10.1159/000343847 10.1002/hep.510290424 10.1111/j.1365-2893.2009.01117.x 10.1136/gut.47.1.131 10.1111/j.1440-1746.2010.06303.x 10.1186/s12885-021-08138-3 10.1111/liv.14475 10.1002/hep4.1823 10.1016/j.jhep.2011.003 10.4254/wjh.v13.i6.699 10.1111/apt.13841 10.1007/s12072-017-9799-9 10.3322/caac.21262 10.1016/j.jhep.2011.03.019 10.21873/invivo.11413 10.3748/wjg.v20.i11.2876 10.3390/ph14080735 10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F 10.1111/j.1349-7006.2011.01875.x 10.1186/s12885-021-08704-9 10.20892/j.issn.2095–3941.2018.0018 10.1002/sim.5328 10.1016/j.bpg.2014.07.018 10.1016/j.cca.2013.08.005 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang. Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang |
Copyright_xml | – notice: Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang. – notice: Copyright © 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang 2022 Liu, Li, Sun, Guan, Gu, Yin, Yao, Liang, Wang, Xing, Zhu, Pawlik, Lau, Shen, Tong and Yang |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fonc.2022.1018396 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2234-943X |
ExternalDocumentID | oai_doaj_org_article_590af4d18bcd43bca900c1d143a34ddb PMC9576185 10_3389_fonc_2022_1018396 |
GrantInformation_xml | – fundername: ; – fundername: ; grantid: 81972726 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 5PM |
ID | FETCH-LOGICAL-c442t-759e2f647effc62d99c24cdba154d59f94bcbc8fe3e9cc04b8be4a431191e30b3 |
IEDL.DBID | M48 |
ISSN | 2234-943X |
IngestDate | Wed Aug 27 01:31:45 EDT 2025 Thu Aug 21 18:39:59 EDT 2025 Thu Jul 10 22:10:51 EDT 2025 Tue Jul 01 00:47:51 EDT 2025 Thu Apr 24 22:56:54 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-759e2f647effc62d99c24cdba154d59f94bcbc8fe3e9cc04b8be4a431191e30b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Cheng-Cheng Zhang, Army Medical University, China; Nanya Wang, First Affiliated Hospital of Jilin University, China Edited by: Wenchuan Wu, Fudan University, China This article was submitted to Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers, a section of the journal Frontiers in Oncology |
OpenAccessLink | https://doaj.org/article/590af4d18bcd43bca900c1d143a34ddb |
PQID | 2726922754 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_590af4d18bcd43bca900c1d143a34ddb pubmedcentral_primary_oai_pubmedcentral_nih_gov_9576185 proquest_miscellaneous_2726922754 crossref_primary_10_3389_fonc_2022_1018396 crossref_citationtrail_10_3389_fonc_2022_1018396 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-30 |
PublicationDateYYYYMMDD | 2022-09-30 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-30 day: 30 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in oncology |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Singal (B1) 2020; 72 Kudo (B36) 2013; 2 Sartorius (B14) 2018; 23 Carr (B31) 2010; 25 Degos (B3) 2000; 47 Marrero (B9) 2018; 68 Yang (B22) 2019; 65 Tzartzeva (B12) 2018; 154 Torre (B2) 2015; 65 Caviglia (B13) 2018; 53 Liu (B37) 2020; 7 (B7) 2018; 69 Toshikuni (B5) 2014; 20 Svobodova (B19) 2018; 32 Gupta (B26) 2021; 21 (B25) 2012; 56 Carr (B30) 2008; 23 Hu (B10) 1999; 29 Nguyen (B17) 2009; 16 Adeniji (B39) 2021; 5 (B6) 2014; 60 Demler (B23) 2012; 31 Toyoda (B38) 2011; 102 Alazawi (B4) 2010; 32 Tarao (B27) 2021; 13 Feng (B33) 2021; 21 Rich (B18) 2014; 28 Choi (B16) 2013; 19 Loglio (B32) 2020; 40 Fattovich (B11) 1997; 112 Schotten (B35) 2021; 14 Yang (B29) 2019; 28 Omata (B24) 2017; 11 Okuda (B34) 2000; 88 Bruix (B8) 2021; 75 Li (B15) 2018; 15 Yi (B20) 2013; 425 Johnson (B21) 2014; 23 Simmons (B28) 2017; 45 |
References_xml | – volume: 72 year: 2020 ident: B1 article-title: Epidemiology and surveillance for hepatocellular carcinoma: New trends publication-title: J Hepatol doi: 10.1016/j.jhep.2019.08.025 – volume: 7 year: 2020 ident: B37 article-title: Validation of the GALAD model and establishment of GAAP model for diagnosis of hepatocellular carcinoma in Chinese patients publication-title: J Hepatocell Carcinoma doi: 10.2147/JHC.S271790 – volume: 112 year: 1997 ident: B11 article-title: Morbidity and mortality in compensated cirrhosis type c: a retrospective follow-up study of 384 patients publication-title: Gastroenterology doi: 10.1053/gast.1997.v112.pm9024300 – volume: 56 year: 2012 ident: B25 article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.001 – volume: 23 year: 2008 ident: B30 article-title: Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2008.05487.x – volume: 53 year: 2018 ident: B13 article-title: Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis publication-title: Scand J Gastroenterol doi: 10.1080/00365521.2018.1459824 – volume: 23 year: 2014 ident: B21 article-title: The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-13-0870 – volume: 19 year: 2013 ident: B16 article-title: Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total- AFP publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i3.339 – volume: 28 year: 2019 ident: B29 article-title: GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-18-0281 – volume: 154 start-page: 1706 year: 2018 ident: B12 article-title: Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.01.064 – volume: 32 year: 2010 ident: B4 article-title: Systematic review: outcome of compensated cirrhosis due to chronic hepatitis c infection publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2010.04370.x – volume: 23 year: 2018 ident: B14 article-title: The biological and diagnostic role of miRNA’s in hepatocellular carcinoma publication-title: Front Biosci (Landmark Ed) doi: 10.2741/4668 – volume: 65 year: 2019 ident: B22 article-title: A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis b publication-title: Clin Chem doi: 10.1373/clinchem.2019.308965 – volume: 75 year: 2021 ident: B8 article-title: Systemic treatment of hepatocellular carcinoma: An EASL position paper publication-title: J Hepatol doi: 10.1016/j.jhep.2021.07.004 – volume: 68 year: 2018 ident: B9 article-title: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases publication-title: Hepatology doi: 10.1002/hep.29913 – volume: 2 year: 2013 ident: B36 article-title: Alpha-fetoprotein-L3: Useful or useless for hepatocellular carcinoma publication-title: Liver Cancer doi: 10.1159/000343847 – volume: 29 year: 1999 ident: B10 article-title: The long-term outcomes of patients with compensated hepatitis c virus-related cirrhosis and history of parenteral exposure in the united states publication-title: Hepatology doi: 10.1002/hep.510290424 – volume: 16 year: 2009 ident: B17 article-title: Hepatitis b-related hepatocellular carcinoma: epidemiological characteristics and disease burden publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2009.01117.x – volume: 47 year: 2000 ident: B3 article-title: Hepatitis c virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death publication-title: Gut doi: 10.1136/gut.47.1.131 – volume: 25 year: 2010 ident: B31 article-title: Low alpha-fetoprotein hepatocellular carcinoma publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2010.06303.x – volume: 21 start-page: 401 year: 2021 ident: B33 article-title: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma publication-title: BMC Cancer doi: 10.1186/s12885-021-08138-3 – volume: 40 year: 2020 ident: B32 article-title: The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy publication-title: Liver Int doi: 10.1111/liv.14475 – volume: 5 year: 2021 ident: B39 article-title: Current and emerging tools for hepatocellular carcinoma surveillance publication-title: Hepatol Commun doi: 10.1002/hep4.1823 – volume: 60 start-page: 392 year: 2014 ident: B6 article-title: EASL clinical practice guidelines: management of hepatitis c virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2011.003 – volume: 13 start-page: 699 year: 2021 ident: B27 article-title: Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma publication-title: World J Hepatol doi: 10.4254/wjh.v13.i6.699 – volume: 45 year: 2017 ident: B28 article-title: Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13841 – volume: 11 year: 2017 ident: B24 article-title: Asia Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update publication-title: Hepatol Int doi: 10.1007/s12072-017-9799-9 – volume: 65 start-page: 87 year: 2015 ident: B2 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 – volume: 69 start-page: 182 year: 2018 ident: B7 article-title: EASL clinical practice guidelines: Management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.03.019 – volume: 32 year: 2018 ident: B19 article-title: PIVKA-II as a potential new biomarker for hepatocellular carcinoma - a pilot study publication-title: In Vivo doi: 10.21873/invivo.11413 – volume: 20 year: 2014 ident: B5 article-title: Hepatitis c-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i11.2876 – volume: 14 year: 2021 ident: B35 article-title: GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis b and c patients publication-title: Pharm (Basel) doi: 10.3390/ph14080735 – volume: 88 year: 2000 ident: B34 article-title: Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000201)88:3<544::AID-CNCR8>3.0.CO;2-F – volume: 102 year: 2011 ident: B38 article-title: Clinical utility of highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein < 20 ng/mL publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2011.01875.x – volume: 21 start-page: 962 year: 2021 ident: B26 article-title: Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-seq datasets and machine learning publication-title: BMC Cancer doi: 10.1186/s12885-021-08704-9 – volume: 15 year: 2018 ident: B15 article-title: Progress in non-invasive detection of liver fibrosis publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095–3941.2018.0018 – volume: 31 year: 2012 ident: B23 article-title: Misuse of DeLong test to compare AUCs for nested models publication-title: Stat Med doi: 10.1002/sim.5328 – volume: 28 year: 2014 ident: B18 article-title: Hepatocellular carcinoma tumour markers: current role and expectations publication-title: Best Pract Res Clin Gastroenterol doi: 10.1016/j.bpg.2014.07.018 – volume: 425 year: 2013 ident: B20 article-title: Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis publication-title: Clin Chim Acta doi: 10.1016/j.cca.2013.08.005 |
SSID | ssj0000650103 |
Score | 2.4025292 |
Snippet | The GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age, alpha-fetoprotein... BackgroundThe GALAD and ASAP scores are two well-recognized algorithms to estimate the risk of hepatocellular carcinoma (HCC) based on gender, age,... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1018396 |
SubjectTerms | alpha-fetoprotein diagnosis hepatitis C virus hepatocellular carcinoma lens culinaris agglutinin-reactive fraction of alpha-fetoprotein Oncology protein induced by vitamin K absence or antagonist-II |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gLggJi-aiMxAkpatYZJzG30FIqRBFSqdSb5bHHaiVIEJu989PxJG61uZQLVztWHM_EfmM_vxHiLUDTokIsqOTdqrqNBZLBog5AWKLXAHwb-exrfXoBny_15U6qL-aEzfLA88AdalO6CGHdog9QoXemLP06pGXeVRAC8uyb1rydYGqegzUnMJiPMVMUZg7j0LNioVIcryZUUC8WokmvfwEylxTJnTXn5JF4mMGi7OZOPhb3qN8X98_ycfgT8ac7777Jc1ailEyv2G7kp-5Ld5yLEh6VgcaJbNXLIcorYv70eL2RR8V0iYXCXDbw_j0TUqXn3EL98NO9l52c2IbcN-KKDRWZ2C5dljJ5Ki5OPn4_Oi1ySoXCA6ixaLQhFWtoKEZfq2CMV-ADuoSkgjbRAHr0baSKjPclYIsELoGMFNZRVWL1TOz1Q0_PhaxAh2QLZ6JWbHCzRlynNq3ypgJHK1HejK_1WW-c0178sCnuYJNYNollk9hskpV4d9vk1yy2cdfDH9hotw-yTvZUkLzHZu-x__KelXhzY3Kb_isebNfTsN1Y1ajaKNVoWIlm4QuLNy5r-uurSaHbpCguAaEX_6OLL8UD_uyZo_JK7I2_t_Q6AaERDyaf_wsYogsM priority: 102 providerName: Directory of Open Access Journals |
Title | ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis |
URI | https://www.proquest.com/docview/2726922754 https://pubmed.ncbi.nlm.nih.gov/PMC9576185 https://doaj.org/article/590af4d18bcd43bca900c1d143a34ddb |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA9zgvgifuJ1OiL4JFTb9PQjA5E63YZ4RZgX7lvJx8k2mK277YXtbX-6OW3usDAEXwrNR5vmJD2_k5z8DmNvAIpSC60jjGm1Ki9dpFHqKLeAOtYmA6DTyPPv-dECvi6z5RbbhLcKHdjdatpRPKnF6vzd5cXVRz_hP5DF6fXte9c2REYoBJmiXuHnd9hdr5gKmqfzgPbHH3NGUQ0o3JxIIZKQLsd9ztufMtFUA6H_BIVOfSj_UkoHD9mDgCZ5NYr_EdvC5jG7Nw_75U_YdXVc_eDHRFXJyf9i3fHD6lv1OSR5wMot9oM3VsNbx0-RHKz7s47vR8MpF7RjWksL_OSxyg0FH2raX2qPV3xwR6S2IWV0GAXPd64C18lTtjj48nP_KAoxFyIDIPqoyCQKl0OBzplcWCmNAGO18lDLZtJJ0Eab0mGK0pgYdKkRlEch3u7DNNbpM7bdtA0-ZzyFzMo4VtJlgkaETLROfJ1SGJmCwhmLN_1bm0BITnExzmtvmJBIahJJTSKpg0hm7O1Nld8jG8e_Cn8iod0UJCLtIaFdndRhXtaZjJUDm5TaWEi1Ub7FJrEeRaoUrNUz9noj8tpPPOps1WC77mpRiFwKUWQwY8VkLEzeOM1pzk4HCm_pzTyPlF78z_fssPt0OzqrvGTb_WqNrzwi6vXusJLgr4fLZHcY838Ave0NFg |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ASAP+Score+versus+GALAD+Score+for+detection+of+hepatitis+C-related+hepatocellular+carcinoma%3A+A+multicenter+case-control+analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Liu%2C+Si-Yu&rft.au=Li%2C+Chao&rft.au=Sun%2C+Li-Yang&rft.au=Guan%2C+Ming-Cheng&rft.date=2022-09-30&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.1018396&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fonc_2022_1018396 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |